Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
Rosalie Fisher, James LarkinDepartment of Medical Oncology, Royal Marsden Hospital, London, United KingdomAbstract: The BRAF inhibitor, vemurafenib, has demonstrated improved progression-free and overall survival compared with chemotherapy in a randomized trial, and represents a new standard of care...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2012-08-01
|
| Series: | Cancer Management and Research |
| Online Access: | http://www.dovepress.com/vemurafenib-a-new-treatment-for-braf-v600-mutated-advanced-melanoma-a10636 |